NewsEvents

Your Yourlocation: Home > Effect of combined inhalation of salmeterol and tiotropium bromide(136310-93-5) on pulmonary function in COPD patients

To investigate the effect of combined inhalation of salmeterol and tiotropium bromide(136310-93-5) on pulmonary function in patients with chronic obstructive pulmonary disease (COPD). Methods: 104 patients with COPD were enrolled in our hospital from February 2014 to October 2015, and were randomly divided into observation group and control group (52 cases). After admission, all patients were given symptomatic supportive therapy, given the control group of patients with salmeterol cardone powder inhalants; in the control group based on the observation group given tiotropium bromide inhalants, a total of 12 weeks of treatment. The lung function and blood gas analysis were measured and compared between the two groups before and after treatment. Results: After treatment, the levels of FEV1, FVC, FEV1 / FVC, Pa O2 and Pa were significantly higher in the observation group than those in the control group (P <0.05). During the treatment group, 2 cases of palpitations occurred in the observation group, 1 case of dry mouth, the control group appeared 2 cases of hoarseness, were not special treatment, self-mitigation. Conclusion: Combined inhalation of salmeterol and tiotropium can significantly improve the pulmonary function of patients with COPD, and does not increase the adverse reactions, it is worthy of clinical promotion.

To observe the clinical effect of tiotropium bromide(136310-93-5) in patients with chronic obstructive pulmonary disease (COPD) with different body mass index (BMI), and to explore whether the body mass index (BMI) has no effect on the clinical efficacy of tiotropium bromide. Methods: 106 patients with moderate to severe chronic obstructive pulmonary disease were treated with tiotropium bromide powder. According to the different body mass index, the patients were divided into low body weight group, normal body weight group and overweight group. Before treatment, (FEV1, FVC) and St George's Respiratory Questionnaire (SGRQ) were measured at the 24th week after treatment for 24 weeks. The difference was observed between the three groups. Results: The lung function and SGRQ score of the three groups were improved after treatment. The improvement rate of FEV1, FVC and SGRQ score in the high body mass index group were lower than those in the normal group and the low body mass index group (P < 0.05). Conclusion: Tiotropium bromide(136310-93-5) can improve lung function and quality of life in patients with moderate to severe chronic obstructive pulmonary disease. The high body mass index (BMI) is an adverse factor affecting the clinical efficacy of tiotropium bromide.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved